LETTER FROM THE EDITOR

S1 The 2011 Education Supplement on Hematopoietic Stem Cell Transplantation
Elizabeth J. Shpall

SECTION I: VIRAL INFECTIONS

S2 Viral Infections in Immunocompromised Patients
Janet Englund, Tobias Feuchtinger, Per Ljungman

SECTION II: MDS

S6 Hematopoietic Stem Cell Transplantation for Treatment of Myelodysplastic Syndromes
Richard Champlin

S9 Nontransplantation Options for Patients with Myelodysplastic Syndromes
Guillermo Garcia-Manero

S11 An Update on the Molecular Pathogenesis of Myelodysplastic Syndromes
Stephen D. Nimer

SECTION III: GENETIC MODIFICATION

S15 Genetic Modification of T Cells
Chiara Bonini, Malcolm K. Brenner, Helen E. Heslop, Richard A. Morgan

SECTION IV: ISCT SESSION

S21 MSCs in Hematopoietic Cell Transplantation
Edwin M. Horwitz, Richard T. Maziarz, Partow Kebriaei

SECTION V: MYELOMA

S30 What Did We Learn in 2010 from the Phase III Trials? Is Maintenance Therapy the New Standard for Myeloma?
Sergio Giralt, Edward Stadtmauer, Phillip McCarthy

SECTION VI: GVL

S33 Graft versus Leukemia Reactivity after Allogeneic Stem Cell Transplantation
J.H. Frederik Falkenburg, Edus H. Warren

SECTION VII: CORD BLOOD

S39 Novel Cord Blood Transplant Therapies
Elizabeth J. Shpall, Catherine M. Bollard, Claudio Brunstein

Continued
SECTION VIII: NMDP SESSION

     Michael Boo, Karen Ballen, Martin Maiers

SECTION IX: GENOMICS

$52  From Trees to the Forest: Genes to Genomics
     Charles Mullighan, Effie Petersdorf, Stella M. Davies, John DiPersio

SECTION X: REGULATORY T CELLS

$58  Natural and Expanded CD4$^+$CD25$^+$ Regulatory T Cells in Bone Marrow Transplantation
     Lucrezia Colonna, Emanuela I. Sega, Robert S. Negrin

SECTION XI: REDUCED INTENSITY

$63  Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia
     John G. Gribben, Chitra Hosing, David G. Maloney

SECTION XII: ACUTE LEUKEMIA

$71  Transplants for the Old But Not for the Young?—The Enigma of Adult ALL
     Rob S. Sellar, Anthony H. Goldstone

$76  Interpreting Data on Transplant Selection and Outcome in Adult Acute Lymphoblastic Leukemia (ALL)
     Jacob M. Rowe

$84  Philadelphia-Positive Acute Lymphoblastic Leukemia—Is Bone Marrow Transplant Still Necessary?
     Adele K. Fielding

SECTION XIII: HAPLOIDENTICAL VS. CORD BLOOD

$89  Point-Counterpoint: Haploidentical Family Donors versus Cord Blood Transplantation
     John Barrett, Eliane Gluckman, Rupert Handgretinger, Alejandro Madrigal

SECTION XIV: MINIMAL RESIDUAL DISEASE

$94  Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell Transplantation
     Nicolaus Kröger, Koichi Miyamura, Michael R. Bishop

SECTION XV: PEDIATRIC BMT

$101 Translational Research Efforts in Biomarkers and Biology of Early Transplant-Related Complications
     Sophie Paczesny, Maribel Diaz-Ricart, Enrique Carerras, Kenneth R. Cooke
S109  Cellular Therapy for Fanconi Anemia: The Past, Present, and Future
Margaret L. MacMillan, Mark R. Hughes, Suneet Agarwal, George Q. Daley

S115  Controversies in the Treatment of CML in Children and Adolescents: TKIs versus BMT?
Meinolf Suttorp, Isaac Yaniv, Kirk R. Schultz

S123  Chronic Granulomatous Disease: Lessons from a Rare Disorder
Brahm H. Segal, Paul Veys, Harry Malech, Morton J. Cowan

S132  Ethical Considerations in Pediatric BMT Donors and Recipients
Naynesh Kamani, John D. Lantos, Doug Myers, Jeffrey P. Kahn

S137  High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant?
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui